Literature DB >> 29631033

An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.

Daniel L Abravanel1, Mizuki Nishino2, Lynette M Sholl3, Chiara Ambrogio1, Mark M Awad4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29631033      PMCID： PMC7102421          DOI： 10.1016/j.jtho.2018.03.026

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  11 in total

Review 1.  BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it.

Authors:  Ioannis Tsamis; Georgia Gomatou; Stavroula Porfyria Chachali; Ioannis Panagiotis Trontzas; Vasileios Patriarcheas; Emmanouil Panagiotou; Elias Kotteas
Journal:  Clin Transl Oncol       Date:  2022-06-21       Impact factor: 3.405

Review 2.  Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.

Authors:  Catherine B Meador; Aaron N Hata
Journal:  Pharmacol Ther       Date:  2020-03-06       Impact factor: 12.310

Review 3.  [Research Progress of Targeted Therapy for BRAF Mutation 
in Advanced Non-small Cell Lung Cancer].

Authors:  Xia Liu; Diansheng Zhong
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-08-20

4.  Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).

Authors:  Kazuko Sakai; Takayuki Takahama; Mototsugu Shimokawa; Koichi Azuma; Masayuki Takeda; Terufumi Kato; Haruko Daga; Isamu Okamoto; Hiroaki Akamatsu; Shunsuke Teraoka; Akira Ono; Tatsuo Ohira; Toshihide Yokoyama; Nobuyuki Yamamoto; Kazuhiko Nakagawa; Kazuto Nishio
Journal:  Mol Oncol       Date:  2020-11-17       Impact factor: 6.603

5.  Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in BRAF V600E-mutated lung cancer.

Authors:  Noriko Hirai; Yutaka Hatanaka; Kanako C Hatanaka; Yuji Uno; Shin-Ichi Chiba; Yasuhiro Umekage; Yoshinori Minami; Shunsuke Okumura; Yoshinobu Ohsaki; Takaaki Sasaki
Journal:  Transl Lung Cancer Res       Date:  2021-09

Review 6.  BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective.

Authors:  Ningning Yan; Sanxing Guo; Huixian Zhang; Ziheng Zhang; Shujing Shen; Xingya Li
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

7.  BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma.

Authors:  Sho Watanabe; Akihiko Shimomura; Takashi Kubo; Masaya Sekimizu; Takuji Seo; Shun-Ichi Watanabe; Akira Kawai; Noboru Yamamoto; Kenji Tamura; Takashi Kohno; Hitoshi Ichikawa; Akihiko Yoshida
Journal:  Mod Pathol       Date:  2020-04-01       Impact factor: 7.842

8.  [Chinese Expert Consensus on Next Generation Sequencing Diagnosis 
for Non-small Cell Lung Cancer (2020 Edition)].

Authors: 
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-09-20

Review 9.  [Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant 
Advanced Non-small Cell Lung Cancer].

Authors:  Na Li; Yanjun Xu; Yun Fan
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-10-20

10.  Identification of genetic variations associated with drug resistance in non-small cell lung cancer patients undergoing systemic treatment.

Authors:  Ruihan Luo; Chuang Ge; Xiao Xiao; Jing Song; Shiqi Miao; Yongyao Tang; Jiayi Lai; Weiqi Nian; Fangzhou Song; Longke Ran
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.